Lennert K Malignant Lymphomas Other than Hodgkin’s disease: histology, cytology, ultrastructure, immunology. Springer: Berlin, 1978.
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al. A revised European American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.
Google Scholar
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48.
Google Scholar
Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53.
Google Scholar
Armand P. Introduction to a review series on mantle cell lymphoma: sand shifting in the darkness. Blood. 2025;145:653–4.
Google Scholar
Khanlari M, Mo H, Kim DH, Weigelin HC, Xu-Monette ZY, Miranda RN, et al. Blastoid and pleomorphic mantle cell lymphoma demonstrate distinct clinicopathologic and genetic features. Am J Surg Pathol. 2023;47:849–58.
Google Scholar
Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.
Google Scholar
Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Nordic Lymphoma Group. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive rst-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115:1530–3.
Google Scholar
He JS, Chen X, Wei GQ, Zhao X, Wang J, Li J, et al. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly diagnosed mantle cell lymphoma patients from China. Medicine. 2019;98:e13741.
Google Scholar
Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann E, Loddenkemper C, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016;34:1386–94.
Google Scholar
Greenwell IB, Staton AD, Lee MJ, Rimsza LM, Beaven AW, Cashen AF, et al. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 2018;124:2306–15.
Google Scholar
Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903–10.
Google Scholar
López C, Silkenstedt E, Dreyling M, Beà S. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma. Blood Adv. 2024;8:3652–64.
Google Scholar
Visco C, Tisi MC, Evangelista A, Di Rocco A, Motta M, Patti C, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185:940–4.
Google Scholar
Ladetto M, Tavarozzi R, Pott C. Minimal residual disease in mantle cell lymphoma: methods and clinical significance. Hematol Oncol Clin North Am. 2020;34:887–901.
Google Scholar
Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Ribrag V, Gisselbrecht C, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215–23.
Google Scholar
Callanan MB, Macintyre E, Delfau-Larue MH, Ghesquières H, Le Gouill S, Haioun C, et al. Predictive power of early, sequential MRD monitoring in peripheral blood and bone marrow in patients with mantle cell lymphoma following autologous stem cell transplantation with or without rituximab maintenance; final results from the lyma-MRD project, conducted on behalf of the lysa group. Blood. 2020;136:12–13.
Google Scholar
Ferrero S, Grimaldi D, Genuardi E, Drandi D, Barbero D, Tavarozzi R, et al. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. Blood. 2022;140:1378–89.
Google Scholar
Hoster E, Delfau-Larue MH, Macintyre E, Doorduijn JK, Walewski J, Hermine O, et al. Predictive value of minimal residual disease for efficacy of rituximab maintenance in mantle cell lymphoma: results from the European mantle cell lymphoma elderly trial. J Clin Oncol. 2024;42:538–49.
Google Scholar
Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677–84.
Google Scholar
Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C, et al. European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–75.
Google Scholar
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Gressin R, et al. LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250–60.
Google Scholar
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Study Group Indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.
Google Scholar
Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944–52.
Google Scholar
Visco C, Chiappella A, Nassi L, Evangelista A, Tisi MC, Spina M, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4:e15–e23.
Google Scholar
Dreyling M, Doorduijn J, Giné E, Aurer I, Hess G, Kersten MJ, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293–306.
Google Scholar
Wang M, Salek D, Belada D, Rule S, Goy A, Jurczak W, et al. Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma. J Clin Oncol. 2025;43:2276–84.
Dreger P, Ahmed S, Bazarbachi A, Sureda A, Giebel S, Finel HA, et al. How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives. Bone Marrow Transplant. 2025;60:759–68.
Google Scholar
Fenske TS, Wang XV, Till BG, Cohen JB, Barta SK, Smith SM, et al. Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) patients (pts) in first complete remission (CR) with undetectable minimal residual disease (uMRD): initial report from the ECOG-ACRIN EA4151 Phase 3 randomized trial. Blood. 2024;144:LBA-6.
Google Scholar
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19:1449–58.
Google Scholar
Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly trial. J Clin Oncol. 2020;38:248–56.
Google Scholar
Tavarozzi R, Ferrero S, Evangelista A, Genuardi E, Drandi D, Barbero D, et al. Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients. Hemasphere. 2025;9:e70102.
Google Scholar
Ribrag V, Safar V, Kluin-Nelemans H, Hoster E, Walewski J, Geisler CH, et al. Rituximab-lenalidomide(R2) maintenance is superior to rituximab maintenance after first line immunochemotherapy in mantle cell lymphoma: results of the MCL R2 elderly clinical trial. Blood. 2021;138:379.
Google Scholar
Dreyling M, Doorduijn JK, Giné E, Hess G, Kersten MJ, Aurer I, et al. Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network. Blood. 2024;144:240.
Google Scholar
Ladetto M, Gutmair K, Doorduijn JK, Dreyling M, Giné E, Ferrero S, et al. Impact of rituximab maintenance added to ibrutinib-containing regimens with and without asct in younger, previously untreated MCL patients: an analysis of the triangle data embedded in the multiply project. Blood. 2024;144:237.
Google Scholar
Wang M, Paludo J, Samuel de Holanda Farias J, Goy A, Jurczak W, Belada D, et al. Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up. ASH. 2025;146:885.
Wang ML, Jurczak W, Jerkeman M, Rule S, Goy A, Zinzani PL, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386:2482–94.
Google Scholar
Eyre TA, Cheah CY, Sarkozy C, Rule S, Dreyling M, Wang M, et al. Mantle cell lymphoma: optimal treatment with bruton tyrosine kinase–targeted approaches. J Clin Oncol. 2025;43:2300–10.
Visco C, Tabanelli V, Sacchi MV, Evangelista A, Spina M, Ferrero S, et al. Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk older patients with mantle cell lymphoma: a phase 2 study by the fondazione italiana linfomi (FIL). Blood. 2023;142:737.
Google Scholar
Ruan J, Martin P, Christos P, Furman RR, Coleman M, Leonard JP, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132:2016–25.
Google Scholar
Lewis DJ, Davies A, Rule S, Kahl BS, Wang M, Jurczak W, et al. Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. Lancet. 2025;406:1953–68.
Dreyling M, Tam CS, Wang M, Yang H, Jurczak W, Zinzani PL, et al. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021;17:255–62.
Google Scholar
Le Gouill S, de Wilde V, Eyre TA, Giné E, Hess G, Rule S, et al. Ibrutinib, venetoclax plus CD20 monoclonal Ab provides very high MRD negativity in previously untreated MCL patients, initial results of OASIS II, a randomized phase 2 trial. Blood. 2024;144:745.
Google Scholar
Hawkes E, Romejko-Jarosinska J, Jurczak W, Rule S, Wang M, Tam CS, et al. Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study. ASH. 2025;8:4539–48.
Ruan J, Leonard JP, Chen GZ, Martin P, Furman RR, Coleman M, et al. Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-naïve mantle cell lymphoma. Blood. 2022;140:175–7.
Google Scholar
Healton S, Soumerai J, Barnes J, Phillips T, Soumerai JD, Armand P, et al. Post-treatment outcomes of TP53-mutant mantle cell lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): durable responses in patients who achieve complete remissions with undetectable MRD. ASH. 2025;146:3569.
Jain P, Ahmed S, Ok CY, Nastoupil LJ, Wang M, Neelapu SS, et al. Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk mantle cell lymphoma: the window-3 clinical trial. ASH. 2025;146:666.
Tilch MK, Schmidt C, Trneny M, Dreyling M, Doorduijn JK, Giné E, et al. Trials in progress: Carman – an international, randomized phase II study evaluating early treatment intensification in patients with high risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B). Blood. 2024;144:4422.3.
Google Scholar
Alzahrani M, Villa D. Management of relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2024;65:1044–54.
Google Scholar
Armitage JO, Longo DL. Mantle-cell lymphoma. N Engl J Med. 2022;386:2495–506.
Google Scholar
Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2021;35:787–95.
Google Scholar
Rule S, Dreyling MH, Goy A, Hess G, Auer R, Kahl BS, et al. Long-term outcomes with ibrutinib versus the prior regimen: a pooled analysis in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with up to 7.5 years of extended follow-up. Blood. 2019;134:1538.
Google Scholar
Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378:1211–23.
Google Scholar
Wang M, Jurczak W, Trneny M, Rule S, Goy A, Zinzani PL, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025;26:200–13.
Google Scholar
Hess G, Dreyling M, Oberic L, Rule S, Jurczak W, Goy A, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol. 2023;202:749–59.
Google Scholar
Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Wang ML, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26:1175–9.
Google Scholar
Wang ML, Jurczak W, Zinzani PL, Goy A, Tam CS, Simpson D, et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988–97.
Google Scholar
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41:555–67.
Google Scholar
Wang M, Siddiqi T, Gordon LI, Avivi I, Holmes H, Ghobadi A, et al. Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024;42:1146–57.
Google Scholar
McCulloch R, Visco C, Eyre TA, Rule S, Dreyling M, Goy A, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189:684–8.
Google Scholar
Sawalha Y, Goyal S, Switchenko JM, Epperla N, Williams ME, Flowers CR, et al. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023;7:2983–93.
Google Scholar
Arcari A, Morello L, Vallisa D, Merli F, Ferretti VV, Angelucci E, et al. Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. Leuk Lymphoma. 2021;62:3474–83.
Google Scholar
Wang M, Cohen J, Shah N, Jurczak W, Zinzani PL, Goy A, et al. Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): final update from the Phase 1/2 BRUIN study. ASH. 2025;146:665.
Herbaux C, Bret C, Bachy E, Cartron G, Thieblemont C, Houot R, et al. Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. Haematologica. 2024;109:3745–50.
Google Scholar
Wang Y, Jain P, Locke FL, Neelapu SS, Ghobadi A, Oluwole OO, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41:2594–606.
Google Scholar
Ahmed N, Thiruvengadam SK, Hamadani M, Ahn KW, Costa LJ, Frey NV, et al. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025;9:5382–96.
Google Scholar
Phillips TJ, Carlo-Stella C, Morschhauser F, Zinzani PL, Hutchings M, Sureda A, et al. Glofitamab in relapsed/refractory mantle cell lymphoma: results from a phase I/II study. J Clin Oncol. 2025;43:318–28.
Google Scholar
Phillips TJ, Matasar M, Eyre TA, Hutchings M, Zinzani PL, Goy A, et al. MCL-339 GLOBRYTE: a phase III, open-label multicenter, randomized trial evaluating glofitamab monotherapy in patients with relapsed or refractory mantle cell lymphoma. Clin Lymphoma, Myeloma Leukemia. 2024;24:S515.
Clausen MR, Lugtenburg P, Hutchings M, Offner F, Radford J, Forconi F, et al. Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: safety profile and antitumor activity. J Clin Oncol. 2021;39:7518.
Google Scholar
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, O’Brien S, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9:e327–e339.
Google Scholar
Wang ML, Assouline S, Kamdar M, Nastoupil LJ, Phillips TJ, Goy A, et al. Fixed Duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed/refractory mantle cell lymphoma: initial results from a phase Ib/II study. Blood. 2023;142:734.
Google Scholar
Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O’Connor OA, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137:2634–45.
Google Scholar
Janakiram M, Depaus J, Wagner-Johnston N, Vose JM, Flowers CR, Smith SD, et al. ABCL-339: Clinical Activity of Loncastuximab Tesirine (Lonca) Plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS-3 Phase 1 Results. Clinical Lymphoma Myeloma and Leukemia. 2021;21:S392.
Caimi PF, Winter AM, Dean RM, Maddocks KJ, Christian BA, Smith SD, et al. Loncastuximab tesirine in combination with venetoclax is safe and shows efficacy in patients with relapsed/refractory non-hodgkin lymphoma. Blood. 2024;144:4499.
Google Scholar
Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, et al. Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid. 2022;1:EVIDoa2100001.
Google Scholar
Kim A, Riedell P, Ryan C, Nastoupil LJ, Wang M, Portell CA, et al. Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO). ASH. 2025;146:2831.
Melani C, Lakhotia R, Pittaluga S, Miljkovic MD, Younes A, Dunleavy K, et al. Phase 1b/2 study of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (vipor) in relapsed/refractory and treatment-naïve mantle cell lymphoma: preliminary analysis of safety, efficacy, and minimal residual disease. ASH. 2024;144:750
Tam CS, Lasica M, Soumerai JD, Roberts AW, Anderson MA, Huang DC, et al. Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma. EHA Library. 2025;4159311:S234.
Wang H, Zhou Q, Li L, Liu Y, Zhang X, Yang J, et al. Bgb-16673, a selective BTK degrader, exhibits deeper inhibition of cancer cell signaling pathways and better efficacy in MCL models. Blood. 2024;144:5833.
Google Scholar
Chavez JC, Nastoupil LJ, Morschhauser F, Salles G, Goy A, Phillips TJ, et al. Efficacy and safety of golcadomide, a novel cereblon E3 ligase modulator (CELMoD) agent, combined with rituximab in a phase 1/2 open-label study of patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2023;142:4496.
Google Scholar
Phillips T, Chen L, Barnhize T, Matasar M, Soumerai JD, Eyre TA, et al. Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment. ASH. 2025;146:883.
